头颈癌患者质子治疗的保险授权与可及性
该研究分析了1519例头颈癌多学科门诊咨询患者和805例寻求质子保险授权患者的资料,发现少数族裔患者拥有对质子治疗不友好保险计划的比例显著更高(24.9% vs 18.4%,P=0.005),且此类保险计划与更长的授权决定时间和更长的任何放疗开始时间相关。
要点
- 少数族裔患者拥有对质子治疗不友好保险计划的比例显著高于非西班牙裔白人(24.9% vs 18.4%,P=0.005)。
- 在寻求质子保险授权的队列中,非西班牙裔白人与少数族裔的质子治疗获批率无显著差异(88% vs 88.2%,P=0.80)。
- 对质子治疗不友好的保险计划与更长的授权决定时间和更长的任何放疗开始时间相关。
核心结论
- 少数族裔患者拥有对质子治疗不友好保险计划的可能性显著更高。
- 这些不友好保险计划与更长的授权决定时间、更低的质子治疗获批率以及更长的任何放疗开始时间相关。
研究设计与样本
- 研究评估了本机构头颈癌多学科门诊咨询的1519例患者以及2020年1月至2022年6月期间寻求质子保险授权的805例患者的人口学特征。
- 根据每位患者的ICD-10诊断代码和具体保险计划前瞻性记录质子治疗保险授权的前景。
- 将对质子束治疗描述为「实验性」或「医学上不必要」的保险计划定义为对质子治疗不友好(PU)的保险。
主要发现
- 在头颈癌多学科门诊咨询患者中,少数族裔患者拥有对质子治疗不友好保险的比例显著高于非西班牙裔白人患者(24.9% vs 18.4%,P=0.005)。
- 在纳入种族、居住地ZIP码平均收入和医疗保险资格年龄的多变量分析中,少数族裔患者拥有对质子治疗不友好保险的比值比为1.25(P=0.041)。
- 在寻求质子保险授权的队列中,非西班牙裔白人与少数族裔患者的质子治疗保险获批率无显著差异(88% vs 88.2%,P=0.80)。
- 对于拥有对质子治疗不友好保险的患者,授权决定的中位时间显著更长(中位15.5天),开始任何模式放疗的中位时间也更长(46 vs 35天,P=0.08)。
- 与非西班牙裔白人患者相比,少数族裔患者从咨询到开始放疗的中位时间更长(37 vs 43天,P=0.01)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated our institutional experience to assess potential racial inequities in insurance coverage for proton therapy in patients with head and neck (HN) cancer. METHODS AND MATERIALS: We examined the demographics of 1519 patients with HN cancer seen in consultation at our HN multidisciplinary clinic (HN MDC) and 805 patients for whom a proton insurance authorization was sought (PAS) from January 2020 to June 2022. The prospects for proton therapy insurance authorization were prospectively noted based on each patient's ICD-10 (International Classification of Diseases, 10th Revision) diagnosis code and their specific insurance plan. Proton-unfavorable (PU) insurance were those plans whose policy describes proton beam therapy as "experimental" or "not medically necessary" for the given diagnosis. RESULTS: For patients seen in our HN MDC, Black, Indigenous, and people of color (BIPOC) were significantly more likely to have PU insurance than non-Hispanic White (NHW) patients (24.9% vs 18.4%, P = .005). In multivariable analysis including race, average income of residence ZIP code, and Medicare eligibility age, BIPOC patients had an odds ratio of 1.25 for PU insurance (P = .041). In the PAS cohort, while there was no difference in the percentage of patients receiving insurance approval for proton therapy between NHW and BIPOC populations (88% vs 88.2%, P = .80), for patients with PU insurance, the median time to determination was significantly longer (median, 15.5 days), and the median time to start any radiation of any modality was longer (46 vs 35 days, P = .08). Compared with NHW patients, the median time from consultation to start of radiation therapy was longer for BIPOC patients (37 vs 43 days, P = .01). CONCLUSIONS: BIPOC patients were significantly more likely to have insurance plans unfavorable to proton therapy coverage. These PU insurance plans were associated with a longer median time to determination, a lower approval rate for proton therapy, and a longer time to start radiation of any modality.
引用
- McDonald MW, Bates JE, McCall NS, et al. Insurance Authorization and Access to Proton Therapy for Patients With Head and Neck Cancers. Int J Radiat Oncol Biol Phys. 2023. PMID: 36889515. doi:10.1016/j.ijrobp.2023.02.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。